Anti-HBV and cytotoxic activities of pyranocoumarin derivatives

被引：96
|
作者：
Su, Chung-Ren [1 ]
Yeh, Sheau Farn [2 ]
Liu, Chih Miem [2 ]
Damu, Amooru G. [1 ]
Kuo, Tsung-Hsiao [1 ]
Chiang, Po-Cheng [3 ]
Bastow, Kenneth F. [4 ]
Lee, Kuo-Hsiung [3 ]
Wu, Tian-Shung [1 ]
机构：
[1] Natl Cheng Kung Univ, Dept Chem, Tainan 701, Taiwan
[2] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan
[3] Univ N Carolina, UNC Eshelman Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, UNC Eshelman Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2009年 / 17卷 / 16期
关键词：
Pyranocoumarin derivatives; Anti-HBV; Cytotoxic; CHRONIC HEPATITIS-B; VIRUS; COUMARINS; THERAPY; ROOT;
D O I：
10.1016/j.bmc.2008.12.007
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Four natural pyranocoumarins clausenidin (1), nordentatin (2), clausarin (3), and xanthoxyletin (4) were isolated from the medicinal plant Clausena excavata. Recently, we found that 1 and 2 suppressed hepatitis B virus surface antigen in HepA2 cells, and in addition, 1-3 showed cytotoxic activity against four human cancer cell lines (A549, MCF7, KB, and KB-VIN). To explore the SAR of 1-4, 17 pyranocoumarin analogues (5-21) were designed and synthesized. Among these analogues, 5 and 10 were the most potent against hepatitis B virus with EC50 values of 1.14 and 1.34 mu M, respectively. The most interesting result in the cytotoxicity assay was the significant activity of 1, 5, and 6 against the multi-drug resistant cell line, KB-VIN, without activity against the KB cell line. These data suggest that these three compounds could be useful hits for developing MDR-inverse drugs. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6137 / 6143
页数：7
相关论文
共 50 条
  • [31] Identification of dihydroquinolizinone derivatives with nitrogen heterocycle moieties as new anti-HBV agents
    Song, Huijuan
    Yang, Shangze
    Wu, Shuo
    Qin, Xiaoyu
    Wang, Ya
    Ma, Xican
    Gong, Jiaqi
    Wei, Meng
    Wang, Apeng
    Wang, Mengyuan
    Lan, Kun
    Guo, Juan
    Liu, Mingliang
    Chen, Xingjuan
    Li, Yuhuan
    Lv, Kai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 268
  • [32] Advanced generation of paeonol-phenylsufonyl derivatives as potential anti-HBV agents
    Huang, Y. P.
    Shih, H. P.
    Liang, Y. C.
    Lin, H. H.
    Lin, M. C.
    Chen, C. W.
    Huang, T. J.
    Kuo, Y. C.
    Han, C. C.
    Hsu, M. H.
    RSC ADVANCES, 2016, 6 (49) : 43556 - 43562
  • [33] Anti-HBV nucleoside analogs.
    Bisacchi, GS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U313 - U313
  • [34] Nucleoside analogs as anti-HBV agents
    Zhou, Xiao-Xiong
    Littler, Eddy
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (09) : 851 - 865
  • [35] Telbivudine.: Anti-HBV agent
    Sorbera, LA
    Castañer, J
    Castañer, RM
    Bayés, M
    DRUGS OF THE FUTURE, 2003, 28 (09) : 870 - 879
  • [36] Chemical constituents from Lonicera japonica flower buds and their anti-hepatoma and anti-HBV activities
    Ge, Lanlan
    Xiao, Lingyun
    Wan, Haoqiang
    Li, Jiemei
    Lv, Kongpeng
    Peng, Shusong
    Zhou, Boping
    Li, Tiyuan
    Zeng, Xiaobin
    BIOORGANIC CHEMISTRY, 2019, 92
  • [37] Adefovir dipivoxil -: Anti-HIV -: Anti-HBV
    不详
    DRUGS OF THE FUTURE, 2000, 25 (08) : 844 - 847
  • [38] Synthesis and anti-HBV activities evaluation of new ethyl 8-imidazolylmethyl-7-hydroxyquinoline-3-carboxylate derivatives in vitro
    Liu, Yajing
    Zhao, Yanfang
    Zhai, Xin
    Liu, Xiuping
    Sun, Lixue
    Ren, Yanxia
    Gong, Ping
    ARCHIV DER PHARMAZIE, 2008, 341 (07) : 446 - 452
  • [39] Emtricitabine -: Coviracil® -: Anti-HIV -: Anti-HBV
    不详
    DRUGS OF THE FUTURE, 2001, 26 (08) : 798 - 800
  • [40] Anti-HBV effect of TAT-HBV targeted ribonuclease
    Jin Ding Jun Liu Cai-Fang Xue Wei-Dong Gong Ying-Hui Li Ya Zhao Department of Etiology
    World Journal of Gastroenterology, 2003, 9 (07) : 1525 - 1528
12345